Idiopathic hypersomnia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:33208G47.1
Who is this for?
Show terms as
4FDA treatments16Active trials39Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Idiopathic hypersomnia (IH) is a chronic sleep disorder where a person feels extremely sleepy during the day even after getting a full night of sleep — or even after sleeping much longer than normal. The word 'idiopathic' means doctors cannot find a clear cause. Unlike narcolepsy, people with IH usually do not have sudden muscle weakness or vivid dream-like hallucinations when falling asleep. IH is also sometimes called 'primary hypersomnia' or 'essential hypersomnia.' The main problem in IH is that the brain does not feel refreshed by sleep, no matter how much a person gets. Many people with IH sleep 10 to 12 hours or more each night and still wake up feeling exhausted. A common and very frustrating symptom is 'sleep inertia' — a heavy, foggy, hard-to-shake grogginess after waking up that can last for hours. Some people describe this as feeling like they are 'drunk' or moving through thick fog. This is sometimes called 'sleep drunkenness.' There is no cure for IH, but treatments can help manage symptoms. For many years, stimulant medications were the main option. In 2021, the FDA approved the first medication specifically for IH — low-sodium oxybate (Lumryz or Xywav) — marking a major step forward. Other medications like modafinil, armodafinil, and amphetamine-based stimulants are also commonly used. Research into the causes of IH is ongoing, and new treatments are being studied.

Also known as:

Key symptoms:

Extreme daytime sleepiness despite long or normal nighttime sleepSleeping 10 to 12 or more hours per night (long sleep time)Severe grogginess or confusion after waking up, sometimes called 'sleep drunkenness'Difficulty waking up from sleep, even with multiple alarmsUnrefreshing naps that do not help with sleepinessBrain fog or difficulty concentrating and thinking clearlyMemory problemsFeeling slow or sluggish throughout the dayDifficulty completing daily tasks due to fatigueAutomatic behaviors — doing things on 'autopilot' without remembering themMood changes such as irritability or low mood related to chronic fatigueHeadachesFeeling cold in the hands and feet

Clinical phenotype terms (11)— hover any for plain English
Brain fogHP:0033630Sleep drunkenessHP:6000456Hypnagogic hallucinationHP:0002519Hypnopompic hallucinationHP:0006896Sleep paralysisHP:0025233SnoringHP:0025267
Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Juvenile

Begins in the teen years

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jun 2026Effects of Operational Naps on Blood Pressure and Performance Among Night Shift Workers

University of Pittsburgh — NA

TrialNOT YET RECRUITING
Mar 2026A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

Harmony Biosciences Management, Inc. — PHASE3

TrialRECRUITING
Feb 2026Association Between Slow Wave Activity and Sleep Inertia

Mahidol University

TrialNOT YET RECRUITING
Nov 2025Study of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance Task

Centre Hospitalier Universitaire de Nīmes

TrialRECRUITING
Nov 2025Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia

Nyree Penn — PHASE1

TrialNOT YET RECRUITING
Oct 2025Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome

Stanford University — PHASE4

TrialNOT YET RECRUITING
Aug 2025A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Centessa Pharmaceuticals (UK) Limited — PHASE2

TrialRECRUITING
Jun 2025A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia

University of Sydney — NA

TrialRECRUITING
May 2025A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

Alkermes, Inc. — PHASE2

TrialRECRUITING
Feb 2025A Study of TAK-360 in Adults With Idiopathic Hypersomnia

Takeda — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

4 available

Lumryz

sodium oxybate· Flamel Ireland Limited dba Avadel Ireland■ Boxed Warning

indicated for the treatment of excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy

Omeprazole

OMEPRAZOLE· PD-Rx Pharmaceuticals, Inc.

Pathologic hypersecretory conditions in adults

Xywav

calcium, magnesium, potassium, and sodium oxybates· Jazz Pharmaceuticals Ireland Limited■ Boxed Warning

indicated for the treatment of excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy

Provigil

Modafinil· Cephalon, Inc.Orphan Drug

Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.

Clinical Trials

16 recruitingView all trials with filters →
Phase 32 trials
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
Phase 3
Actively Recruiting
PI: David Seiden, MD (Harmony Biosciences Management, Inc.) · Sites: Santa Monica, California; Miami, Florida +10 more · Age: 1899 yrs
Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
Phase 3
Active
· Sites: Boulder, Colorado; Winter Park, Florida +5 more · Age: 1875 yrs
Phase 41 trial
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
Phase 4
Actively Recruiting
PI: Chad Ruoff, MD (Mayo Clinic) · Sites: Phoenix, Arizona; Redwood City, California +2 more · Age: 1865 yrs
Phase 24 trials
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
Phase 2
Actively Recruiting
PI: Medical Director (Alkermes, Inc.) · Sites: Cullman, Alabama; Phoenix, Arizona +46 more · Age: 1870 yrs
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Phase 2
Actively Recruiting
· Sites: Auburn, Alabama; Santa Ana, California +12 more · Age: 1865 yrs
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
Phase 2
Actively Recruiting
PI: Study Director (Takeda) · Sites: Redwood City, California; Santa Ana, California +27 more · Age: 1870 yrs
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Phase 2
Actively Recruiting
· Sites: Auburn, Alabama; Chandler, Arizona +27 more · Age: 1865 yrs
N/A4 trials
Deciphering the Interactions Between Food Intake, Sleepiness, and Nighttime Sleep Quality in Patients With Type 1 Narcolepsy and Idiopathic Hypersomnia
N/A
Actively Recruiting
PI: Laure PETER-DEREX, MD-PhD (Hospices Civils de Lyon) · Sites: Clermont-Ferrand; Lyon · Age: 1865 yrs
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
N/A
Actively Recruiting
PI: Laure PETER-DEREX, Professor (Hospices Civils de Lyon) · Sites: Lyon · Age: 1865 yrs
A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia
N/A
Actively Recruiting
PI: Elizabeth A Machan, PhD (University of Sydney) · Sites: Macquarie Park, New South Wales · Age: 1899 yrs
Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence
N/A
Actively Recruiting
· Sites: Montpellier · Age: 899 yrs
Other4 trials
Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
Enrolling by Invitation
PI: Chad Ruoff, MD (Mayo Clinic) · Sites: Scottsdale, Arizona · Age: 1875 yrs
International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
Actively Recruiting
PI: Claudio L Bassetti, Prof. (Insel Gruppe) · Sites: Bern · Age: 1070 yrs
Study of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance Task
Actively Recruiting
PI: Elisa EVANGELISTA (CHU de Nimes) · Sites: Nîmes · Age: 1854 yrs
Mainz Register of Patients With Sleep Disorders
Actively Recruiting
· Sites: Mainz, Rhineland-Palatinate · Age: 18120 yrs

Specialists

Showing 25 of 39View all specialists →
LM
Lynn Marie Trotti, MD
Specialist
PI on 2 active trials
EE
Elisa EVANGELISTA
SACRAMENTO, CA
Specialist
PI on 1 active trial
LP
Laure PETER-DEREX, Professor
Specialist
PI on 1 active trial
RM
Rachel DEBS, MD
Specialist
PI on 2 active trials
CP
Christopher Drake, PhD
Specialist
PI on 1 active trial
LM
Laure PETER-DEREX, MD-PhD
Specialist
PI on 1 active trial
CP
Claudio L Bassetti, Prof.
Specialist
PI on 1 active trial
LM
Lynn Marie Trotti, MD, MSc
Specialist
PI on 2 active trials
YD
Yves DAUVILLIERS
Specialist
PI on 2 active trials
YP
Yves DAUVILLIERS, MD PhD
Specialist
PI on 2 active trials
ML
Morgan Lam
Specialist
PI on 3 active trials9 Idiopathic hypersomnia publications
EP
Elizabeth A Machan, PhD
Specialist
PI on 1 active trial
S(
Sheila Sivam, PhD; MD; FracP; BSc (Med)
PITTSBURGH, PA
Specialist
PI on 1 active trial1 Idiopathic hypersomnia publication
EP
Eric Zhou, PhD
Specialist
PI on 1 active trial
IP
Isabelle ARNULF, MD, PhD
Specialist
PI on 2 active trials
DP
David Rye, MD, PhD
ATLANTA, GA
Specialist
PI on 1 active trial
MP
Monira I. Aldhahi, PhD
Specialist
PI on 1 active trial
MM
Maria Antonia QUERA SALVA, MDPhD
Specialist
PI on 1 active trial
MT
Michael J Thorpy
BRONX, NY
Specialist
5 Idiopathic hypersomnia publications
RB
Richard K Bogan
COLUMBIA, SC
Specialist
4 Idiopathic hypersomnia publications
TD
Thomas J Dye
CINCINNATI, OH
Specialist
2 Idiopathic hypersomnia publications
MS
Marek Susta
Specialist
2 Idiopathic hypersomnia publications
EW
Esther Werth
Specialist
PI on 1 active trial
ES
Emilia SFORZA
Specialist
PI on 1 active trial
MM
Mitchell Miglis
MELBOURNE, FL
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources
Lumryz(sodium oxybate)Flamel Ireland Limited dba Avadel Ireland

WAKIX

Harmony Biosciences Management, Inc.

WAKIX — Contact Harmony Biosciences Management, Inc.

Unverified — confirm before calling
Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to Idiopathic hypersomnia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Idiopathic hypersomniaForum →

No community posts yet. Be the first to share your experience with Idiopathic hypersomnia.

Start the conversation →

Latest news about Idiopathic hypersomnia

5 articles
NewsFDA
FDA Approves CABERGOLINE
CABERGOLINE (CABERGOLINE) received FDA approval.
NewsSLEEPApr 16, 2026
Perspectives on idiopathic hypersomnia: diagnostic challenges, unknown pathophysiological, and emerging therapeutic strategies.
Idiopathic hypersomnia is a rare chronic neurological condition that may be characterized by excessive daytime sleepiness, and/or prolonged nocturnal sleep, and
NewsSLEEPApr 16, 2026
Sleep time and SOREMPs features support idiopathic hypersomnia and narcolepsy type 2 as a single disease entity.
Idiopathic hypersomnia (IH) and narcolepsy type 2 (NT2) are rare hypersomnolence disorders with unknown pathophysiology. Recent evidence suggests they may belon
NewsJOURNAL OF SLEEP RESEARCHMar 20, 2026
Dynamic Functional Network Connectivity Patterns Distinguish Neurobiological Substrates of Narcolepsy Type 1 and Idiopathic Hypersomnia: Potential Biomarkers From Resting-State fMRI.
This study aimed to explore dynamic functional network connectivity (dFNC) differences between narcolepsy type 1 (NT1), idiopathic hypersomnia (IH), and healthy
NewsJOURNAL OF SLEEP RESEARCHMar 20, 2026
Age at Onset and Delays in Diagnosis of Central Disorders of Hypersomnolence Over the Past 30 Years.
Patients with narcolepsy type 1 (NT1), type 2 (NT2), idiopathic hypersomnia (IH) usually suffer from symptoms for years, even decades, before being diagnosed. W
See all news about Idiopathic hypersomnia

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What tests do I need to confirm the diagnosis of idiopathic hypersomnia and rule out other causes?,Which medication would you recommend starting with, and what are the risks and benefits?,Am I a candidate for Xywav (low-sodium oxybate), and how do I access it?,What lifestyle changes or sleep schedule adjustments might help my symptoms?,Are there any clinical trials for IH that I might be eligible to join?,What accommodations can you help me document for school or work?,How will we know if my treatment is working, and how often should I follow up?

Common questions about Idiopathic hypersomnia

What is Idiopathic hypersomnia?

Idiopathic hypersomnia (IH) is a chronic sleep disorder where a person feels extremely sleepy during the day even after getting a full night of sleep — or even after sleeping much longer than normal. The word 'idiopathic' means doctors cannot find a clear cause. Unlike narcolepsy, people with IH usually do not have sudden muscle weakness or vivid dream-like hallucinations when falling asleep. IH is also sometimes called 'primary hypersomnia' or 'essential hypersomnia.' The main problem in IH is that the brain does not feel refreshed by sleep, no matter how much a person gets. Many people with

How is Idiopathic hypersomnia inherited?

Idiopathic hypersomnia follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Idiopathic hypersomnia typically begin?

Typical onset of Idiopathic hypersomnia is juvenile. Age of onset can vary across affected individuals.

Are there clinical trials for Idiopathic hypersomnia?

Yes — 16 recruiting clinical trials are currently listed for Idiopathic hypersomnia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Idiopathic hypersomnia?

25 specialists and care centers treating Idiopathic hypersomnia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Idiopathic hypersomnia?

2 patient support programs are currently tracked on UniteRare for Idiopathic hypersomnia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.